https://www.taxtmi.com/news?id=63292 A bilateral arrangement grants a zero-tariff rate on UK-origin pharmaceuticals, pharmaceutical ingredients, and medical technology exported to the United States for at least three years, conditioned on UK drug firms increasing investment and job creation in the United States and on the UK government increasing spending on new treatments. en-us Mon, 01 Dec 2025 22:46:03 +0530 Mon, 01 Dec 2025 22:46:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=63292 A bilateral arrangement grants a zero-tariff rate on UK-origin pharmaceuticals, pharmaceutical ingredients, and medical technology exported to the United States for at least three years, conditioned on UK drug firms increasing investment and job creation in the United States and on the UK government increasing spending on new treatments. News - Mon, 01 Dec 2025 22:46:03 +0530 https://www.taxtmi.com/news?id=63292